Engflag

Lidoderm

Quick links to important sections

Lidoderm

Selected form

Lidoderm_EN

Method of action: Anesthetic, Antiarrhythmic, Antipruritics, Incl. Antihistamines, Anesthetics, Etc, Local Anesthetic, Lubricating

Treatment option: Pain, Neuralgia

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lidoderm

This foundational section defines the medicine entity, its composition, classification, and general purpose, strictly avoiding details on dosage, specific conditions treated, safety, or administration.

Property Description
Active ingredient Lidocaine Hydrochloride
Form Transdermal System (Patch)
Pharmacological Class Local Anesthetic, Analgesic Agent
Route of Administration Topical, Dermal
Origin Synthetic (Amide-type)

What Type of Medicine is Lidoderm and How is it Classified?

Lidoderm is a prescription-only medicine formulated as a transdermal system, containing the single active substance, Lidocaine Hydrochloride. It is classified as an Analgesic Agent and a Local Anesthetic belonging to the amide-type family, defining its synthetic chemical origin. Its classification means its primary action is to interrupt the transmission of pain signals in the peripheral nervous system rather than altering central nervous system function. Lidocaine acts primarily by reversibly blocking sodium channels, thereby stabilizing the neuronal membranes. This action helps to mute nerve activity in the applied area and is recognized for its effectiveness in localized discomfort.

Understanding the Lidoderm Transdermal Patch and Composition

The physical form of the medication is a flexible, adhesive patch, defined as a transdermal system, which facilitates the topical administration of the medicine. This system is a single-ingredient product where the active substance, Lidocaine, is embedded within an aqueous-based hydrogel adhesive matrix. This pharmaceutical preparation ensures a controlled, extended-release formulation, allowing the drug to pass through the skin layers into the target tissue. The patch's design, which provides the single-ingredient 5% concentration, is a key distinguishing factor from creams or gels, ensuring continuous delivery of the drug to the localized area.

What is the Core Benefit of a Localized Analgesic?

The core benefit of the Lidoderm patch lies in its ability to achieve localized numbing or anesthesia by directly affecting nerve function. The active ingredient operates as a sodium channel blocker, which stabilizes the neuronal membranes to prevent the necessary electrical activity. This inhibition of nerve signal conduction provides localized pain relief, offering the advantage of focused action with minimal systemic action. The use of a transdermal system makes it particularly suitable for managing persistent, localized discomfort, where sustained topical administration is beneficial.

Regulatory References

  1. Lidocaine - StatPearls - NCBI Bookshelf

What side effects are possible with Lidoderm?

The official safety profile for the Lidocaine 5% patch is documented by regulatory authorities, classifying and organizing potential adverse reactions primarily based on the localized route of administration.

Documented Adverse Reactions and Frequencies

Adverse effects are categorized by frequency, which reflects the incidence observed in clinical use and post-marketing surveillance:

  • Common Reactions (ge 1%): The most frequently reported effects are generally confined to the patch application site, classified under Skin and subcutaneous tissue disorders. These include Erythema (redness), Pruritus (itching), Rash, and Dermatitis. A Burning sensation and minor Skin irritation are also commonly documented.
  • Uncommon Reactions (0.1% to < 1%): Less frequent skin reactions include Contact Dermatitis, Exfoliation (skin flaking), and localized Edema (swelling).
  • Rare Systemic Reactions: Systemic effects such as Dizziness or Nervousness are rarely reported, typically only arising when systemic concentrations of the active substance are elevated.

Serious Safety Considerations

While systemic exposure is low with proper topical use, the regulatory label documents the potential for serious adverse reactions associated with lidocaine, including severe Hypersensitivity reactions, such as Anaphylactic reactions. Warnings against Systemic Toxicity (e.g., cardiac or central nervous system effects) are noted, specifically when the product is used incorrectly, resulting in high plasma concentrations.

Population-Specific Safety Notes

Safety constraints are specified for certain patient groups. Caution is formally advised for patients with severe hepatic impairment because the liver is essential for the metabolism and clearance of lidocaine. Caution is also noted for older adults due to the higher likelihood of reduced organ function.

Regulatory Safety Restrictions

The most important safety constraint is the requirement that the patch be applied only to intact, non-damaged skin to strictly minimize the risk of increased systemic absorption. Furthermore, regulatory documents note that concurrent use of other products containing local anesthetics may contribute to an undesirable increase in the overall systemic burden of the active substance.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose from the Lidoderm patch is related to excessive systemic absorption of lidocaine, which occurs if the patch is applied to overly large areas or used for longer than the recommended duration. Toxic effects are generally expected when the lidocaine concentration in the blood exceeds 5 mcg/mL, leading to systemic toxicity symptoms primarily affecting the Central Nervous System (CNS) and Cardiovascular System.

Documented Overdose Manifestations and Complications

Symptoms documented in official labeling include CNS effects such as dizziness, confusion, nervousness, and uncontrolled muscle twitching. Cardiovascular signs may involve a slow or irregular heart rate. In severe cases, toxicity can progress to life-threatening outcomes, including seizures, loss of consciousness, and cardiovascular collapse.

A specific, serious complication associated with lidocaine is Methemoglobinemia, which is characterized by pale, gray, or blue-colored skin and shortness of breath. Patients with severe hepatic disease and smaller patients are officially noted to be at a greater risk of developing toxic blood concentrations.

Required Emergency Actions

The most important initial action for a suspected overdose is to immediately remove the patch.

Urgent medical attention must be sought if any signs of systemic toxicity are observed, especially if symptoms are severe or if any signs of Methemoglobinemia are present. Immediate contact with emergency services is required if the victim has collapsed, has trouble breathing, or is unresponsive. Management involves close patient monitoring, supportive care, and symptomatic treatment, with Methylene Blue documented as a treatment for Methemoglobinemia.

Therapeutic Uses of Lidoderm

What Lidoderm Treats: Main Uses and Benefits

Lidocaine patch 5% (sold under the brand name Lidoderm, among others) is commonly used to help with symptoms related to physical discomfort in contexts involving heightened systemic burden. This specific condition is an example of a condition characterized by periods of heightened symptoms, typically involving chronic nerve pain following a shingles infection (herpes zoster).

The medicine is applied topically across domains where additional symptomatic support is needed. It is considered relevant within therapeutic domains that involve certain distressing symptoms. The topical application helps address symptom clusters that may become intense or disruptive and contributes to improved comfort during periods of heightened symptoms.

This delivery method generally provides supportive relief that helps ease the overall symptom burden associated with localized discomfort. It may assist with maintaining functional stability and provides supportive relief when symptoms interfere with routine activities. This approach is commonly used in clinical settings that involve acute or unstable symptom patterns.

“This provides support that helps ease the overall symptom burden and may help patients cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Symptoms Related to Physical Discomfort

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Lidoderm — Official Regulatory Information

The eligibility profile for the Lidoderm (Lidocaine Patch 5%) transdermal system is defined by governmental regulatory documents, outlining populations permitted, restricted, or prohibited from using the medicine.

Eligibility Scope
Populations for whom use is allowed: Adults (18 years and older) and Geriatric Patients.
Populations for whom use is not recommended: Pediatric Patients (under 18 years) as safety and effectiveness have not been established.
Populations for whom use is contraindicated: Patients with a known history of hypersensitivity to the active substance, Lidocaine, or to any other local anesthetics of the amide type.
Age-Related and Condition-Specific Eligibility
Age-related eligibility rules: Safety and effectiveness are not established for pediatric patients (under 18 years). No significant difference in safety was observed in older adults.
Condition-specific eligibility rules: Use requires caution in patients with severe hepatic disease due to the potential for increased systemic exposure and toxic blood concentrations.
Pregnancy and lactation status: Use during pregnancy is categorized as Category B (US FDA) and is permitted only if clearly needed. Caution should be exercised when administered to a nursing mother, as lidocaine is excreted in human milk.

This regulatory structure strictly defines who may use the patch, with contraindications based on allergic history and prohibitions on applying the patch to non-intact skin, such as broken or inflamed areas.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory information regarding drug interactions for Lidoderm focuses primarily on the risk of additive or synergistic systemic toxicity when used with specific classes of medicinal products.

Documented Interaction Domains

  • Class I Antiarrhythmic Drugs: Products such as tocainide and mexiletine are cited in official labeling. The combination is documented as potentially leading to an additive and potentially synergistic increase in toxic effects. Regulatory guidance advises that Lidoderm be used with caution in patients receiving these agents due to this elevated risk of systemic toxicity.

  • Other Local Anesthetic Agents: Official regulatory documents require careful consideration of the total absorbed local anesthetic load when Lidoderm is used concurrently with other products containing local anesthetic agents. The requirement is to account for the total amount absorbed from all formulations to avoid exceeding systemic tolerance and minimize the risk of cumulative systemic toxicity.

Contextual Summary

These interaction constraints establish a clear framework for safe co-administration, specifically by requiring caution with antiarrhythmic medicines that share similar toxicological profiles and by mandating a procedural check on the cumulative exposure from all local anesthetic sources. This structure ensures that the primary interaction concern—systemic lidocaine toxicity—is managed through calculated dose assessment and clinical vigilance.

Mechanism of Action

How Lidoderm Works — Pharmacodynamics

Lidoderm's mechanism centers on the pharmacodynamic action of its active compound, lidocaine, within the peripheral nervous system. Upon topical application, lidocaine diffuses to local nerve endings and acts as a voltage-gated sodium channel ( Na v) inhibitor.

This mechanism involves the drug entering the neuron and physically binding within the inner pore of the Na v channel, primarily targeting the Na v 1.7 and Na v 1.8 subtypes associated with sensory nerve conduction. The binding event prevents the necessary influx of sodium ions ( Na^+), which is essential for rapid cell depolarization.

By disrupting this critical ionic flow, the drug prevents the generation and propagation of action potentials along the primary afferent nociceptors ( Adelta and C fibers). This failure to transmit electrical impulses results in the localized dampening of peripheral nociceptive signaling and a transient stabilization of the neuronal membrane, thereby producing a localized reduction in sensory input at the site of administration.

Dosage and Administration Information

How to Use Lidoderm (Lidocaine Patch 5%)

Lidoderm patches are used for the localized relief of pain associated with post-herpetic neuralgia. It is crucial to follow the prescribed regimen to ensure proper efficacy and safety.

Application Instructions

  • Skin Preparation: Apply the patch only to intact, clean, and dry skin that covers the most painful area. Do not place the patch on broken, irritated, inflamed skin, or open wounds, as this may increase the absorption of lidocaine into the bloodstream and increase the risk of systemic effects.
  • Preparation: The patch may be cut into smaller sizes with scissors prior to removing the release liner to better fit the painful area.
  • Placing the Patch: Remove the protective liner and immediately apply the adhesive side of the patch to the skin. Press down firmly to ensure complete contact, especially around the edges.

Dosing and Duration

Parameter Instruction Safety Note
Maximum Patches Apply up to a maximum of three (3) patches simultaneously. Do not use more than the prescribed number of patches.
Wearing Time Apply only once for up to 12 hours within a 24-hour period. Excessive dosing or application time can lead to serious adverse effects.
Patch-Free Period A 12-hour patch-free period must follow each 12-hour application period. This period is essential to reduce the risk of lidocaine accumulation.

Important Safety Reminders

  • Heat: Avoid placing external heat sources, such as heating pads or electric blankets, directly over the patches, as this may increase the amount of lidocaine absorbed.
  • Handling: Wash your hands immediately after handling the patch to avoid contact with the eyes or mouth. If eye contact occurs, wash out the eye immediately with water or saline.
  • Disposal: After use, fold the patch so the adhesive side sticks to itself and dispose of it safely, ensuring it is out of the reach of children and pets. Even used patches contain residual lidocaine that can be harmful.

Recent Clinical Evidence

Lidoderm: Recent Clinical Evidence

Research has evaluated the role of the Lidocaine 5% patch in managing localized chronic neuropathic pain. The primary condition studied is Post-Herpetic Neuralgia (PHN), with extended research exploring other conditions like Painful Diabetic Peripheral Neuropathy (PDPN).

Studies have assessed reported changes in patient pain scores, quality of life, and associated symptoms like tingling and burning. These studies focus on both short-term use and the documented effects of longer-term application.

Key Clinical Trial Findings

Condition Study Type Key Outcomes Evaluated
Post-Herpetic Neuralgia (PHN) Randomized Controlled Trials (RCTs) Changes in daily pain intensity scores compared to vehicle patch; reduction in allodynia (pain from non-painful stimuli).
Diabetic Neuropathy (PDPN) Observational, Systematic Reviews Differences in pain scores and improvements in daily functioning compared to baseline.

Combination Therapy and Safety Profile

Studies have compared the outcomes of combination therapy to monotherapy, often when systemic treatments such as gabapentinoids or pregabalin are used concurrently. These studies aim to identify differences in reported outcomes and adverse event rates when the topical drug is used alongside oral analgesic agents.

  • Systemic Absorption: Due to limited systemic absorption, clinical trials documented low plasma lidocaine concentrations. This has been noted as a potential factor in its localized action.
  • Adverse Events: The documented adverse events in research were typically localized to the application site, including redness, burning, or discomfort. Systemic adverse events, such as those related to the cardiovascular or central nervous system, were reported less frequently in comparison to studies of oral treatments.

Frequently Asked Questions (FAQ)

Common questions about Lidoderm (FAQ)

Q: What is the main use of the Lidoderm patch?

A: The Lidoderm patch is indicated for the relief of pain associated with Post-Herpetic Neuralgia (PHN). PHN is a painful condition that can occur after a shingles (herpes zoster) rash has cleared.

Q: How does the Lidoderm patch work to help with pain?

A: The patch is a localized delivery system containing lidocaine. Lidocaine is an anesthetic that is thought to produce its effect by stabilizing neuronal membranes and inhibiting the ionic fluxes required for the initiation and conduction of impulses. When applied to the painful area, the patch delivers lidocaine locally to the site.

Q: Can the Lidoderm patch be used for types of pain other than Post-Herpetic Neuralgia?

A: The Food and Drug Administration (FDA) has specifically approved the Lidoderm patch for treating the pain of Post-Herpetic Neuralgia (PHN). Use for other types of pain, while occasionally discussed in medical literature, is considered off-label, and patients should consult a healthcare provider for any use outside of the approved indication.

Q: What are the common local side effects associated with the Lidoderm patch?

A: Since the patch is applied directly to the skin, most common side effects are localized to the application site. These may include redness, skin irritation, dermatitis, and itching. Systemic absorption is generally low, but patients should report any unusual reactions to their doctor.

Q: Is the Lidoderm patch a controlled substance?

A: No. Lidoderm (lidocaine patch 5%) is an anesthetic and is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA).

How should Lidoderm be stored and disposed of?

Storing and Disposing of Lidoderm (Lidocaine Patch 5%)

Lidoderm patches must be stored at Controlled Room Temperature, defined as 20 to 25 C (68 to 77 F). To maintain stability, the patch must be kept in its original sealed envelope (sachet) and protected from excess heat and moisture. Do not store the patches outside the sealed sachet before immediate use.

Child Safety and Disposal

The medicine must be stored out of the sight and reach of children and pets at all times. This is crucial because a significant amount of the drug remains in a used patch, posing a risk of serious harm if ingested.

To dispose of a used patch, immediately fold it in half so the adhesive sides stick firmly together. The folded patch must then be safely discarded into the trash, away from access by children and pets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagUSA

Equivalent of Lidoderm found in:

A-Z Index: